This appendix presents further details on our data set to (a) allow interested readers to inspect individual observations near the Gavi eligibility threshold which may have inordinate influence on our treatment effect estimates, and (b) enable other researchers to more easily replicate what we have done.
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Created using gross national income per capita, Atlas method (current US$) data drawn from original PDFs of the World Banks World Development Indicator (WDI) publications, when available. Data from the 2013 WDI report was not available in PDF format and was downloaded from the World Bank's DataBank using Stata. For several countries, these reports provide only an income category due to a lack of data. When an estimate for GNI is not available for low-income countries, we impute the mean GNI for LICs in that year. See Section A.7 for more information.
World Bank (1 2 3 4)
Treatment
Created from Gavi disbursement data 2000-2013, reported by program year, the year in which vaccines/programs are implemented.
Gavi
Immunization coverage Percent of children who have completed a series of the following vaccines by age 1: diphtheria, pertussis and tetanus (DPT), hepatitis B (HepB), Haemophilus influenzae type B (Hib), measles and rotavirus (rota). For rota, coverage rates were imputed as 0 before the year the vaccine was introduced in a country. We use the WHO/UNICEF official coverage estimate (WUENIC) for years [1995] [1996] [1997] [1998] [1999] [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] [2010] [2011] [2012] [2013] .
WHO

Income classification Historical World Bank income group classifications World Bank
Population We use population estimates for the population under age 1, 5 and total population. This estimate is based on the de facto definition of population, which counts all residents regardless of legal status or citizenship-except for refugees not permanently settled in the country of asylum.
World Bank
Gavi-purchased doses Our estimate of the number of doses purchased by Gavi is constructed using Gavi's data on disbursements and UNICEF data on total doses purchased and total spending by vaccine worldwide.
Estimates account for buffer stocks and country-reported (when unavailable, mean) wastage rates. We use disbursements from the previous year to estimate doses, as vaccination rates are calculated as children who have been vaccinated by age 1 and children vaccinated as a result of these doses will not be measured until the following year. 
UNICEF Gavi
WHO
Mortality rate Probability of a child dying between birth and age 1 (infant mortality) or age 5 (under-5 mortality), expressed as a rate per 1,000 live births. Data is available in 5-year increments.
Disease-specific mortality rates Probability of a child under age 5 dying due to diseases preventable by 6 vaccines, expressed as a rate per 100,000 population. Data is reported by cause (e.g. diphtheria) and aggregated by vaccine. GBD does not report deaths due to all diseases preventable by the 6 vaccines. For example, the pneumococcal and Hib vaccines prevent both meningitis and pneumonia caused by those types of bacteria, but GBD does not provide data on deaths due to pneumococcal or H influenzae type B pneumonia. Riley, et al. (1986) estimate that the pneumococcal vaccine prevented 50% of deaths due to lower respiratory infections (LRIs) in Papua New Guinea. 
IHME
Health system financing Vaccine financing data is drawn from the JRF, which began recording financing figures in 2006, and Gavi disbursement data. Government spending is drawn from the JRF and includes all funds allocated through the national government budget. Total spending on vaccines, as reported in the JRF, reports financing from all sources, including government, donors, out-of-pocket and informal private payments. Spending is expressed as a per infant rate using World Bank population figures. Data is available until 2013.
WHO World Bank Gavi
Non-income eligibility Created using country official vaccination coverage rates, which Gavi used to determine eligibility for ISS and NVS funding during phases 1 and 2.
WHO
A.2 Changes in eligibility
We're particularly interested in countries whose eligibility status changed over time, and whether Gavi's actual disbursement followed suit. As described in the main text, for the period covered by our sample income eligibility was evaluated at four points in time, using GNI data from 1998, 2003, 2009, 2010 and 2011 . Twenty-one countries experienced a change in eligibility, either because their income changed or the eligibility line changed around them. These twenty-one countries are listed in Table 2 . Of these twenty-one countries, seventeen initially qualified and then subsequently became ineligible.
2 In fourteen of these seventeen cases, Gavi continued to disburse aid in subsequent periods -exceptions being 2 Other cases are more complex. Bolivia entered eligibility partway through phase 1 and subsequently exited eligibility, but received Gavi aid in all periods. Equatorial Guinea became eligible in phase 2, but has never received Gavi aid. Kiribati is the sole case of a country that 'fell' into eligibility and began receiving Gavi assistance for the first time after phase 1. become ineligible to continue to receive funding support approved earlier for an agreed period of time, typically 5 years. This policy explains a number of the cases in which Gavi disbursed funding to ineligible countries.
4
The bottom line here is that Gavi disbursement appears to be determined primarily by income eligibility in phase 1. In most but not all cases, subsequent changes to eligibility did not lead to the appearance or disappearance of a Gavi country program. 
A.3 Non-income eligibility
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A.4 Alternative counterfactuals 
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A.5 Causes of under-5 mortality
In order to estimate the potential for subsidized vaccines disbursed by Gavi to impact child mortality, it is necessary to know who many people were dying of the relevant diseases in countries near Gavi's income threshold before Gavi began providing funding. Table 5 describes the diseases each vaccine protects against and the amount Gavi has spent on those vaccines between 2000 and 2013. In Figure 1 , we estimate the disease-specific mortality rate at various points in time using estimates from the Global Burden of Disease (GBD) project. For each disease or group of diseases, we fit a local polynomial regression of death rates on baseline GNI for countries below the Gavi threshold of $1,000 in 1998.
For all diseases, mortality rates are unsurprisingly declining over time and with per capita income. Overall, mortality rates before the widespread roll-out of Gavi aid were highest for measles, pneumococcal disease and rotavirus, though measles mortality had been dramatically reduced prior to Gavi's launch and the pneumococcal vaccine was not. The main conclusion we take from Figure 1 is that there was limited scope for further mortality reduction through Gavi-funded vaccines by the 2000s in countries near the eligibility threshold. Hepatitis B is a viral infection that attacks the liver and causes both acute and chronic disease. Most mortality occurs many years after the infection, therefore mainly in adulthood. Data are based on modeled estimates from the Global Burden of Disease database. Each graph presents a local polynomial regression of estimated death rates (age-standardized rates per 100,000 children) -at up to three points in time -for children under five years old on countries' 1998 log per capita GNI.
A.6 Sample countries by Gavi phase
The rest of this appendix provides a partial list of the data used in the regressions, with a separate table for each of the five Gavi phases, as we define them ( We arrange each table in order by the GNI used to determine eligibility, i.e., the forcing variable in the regression discontinuity design. The logic of producing separate tables by phase is that eligibility was re-evaluated at the outset of each phase. As a consequence, our sample and the running variable, GNI, are updated in each phase. Our sample includes countries within a bandwidth of 2 log points of the eligibility cut-off at the time eligibility was evaluated. The tables also present the lower and upper bound for the other bandwidths used in our analyses.
For phase 1, the full sample of countries reporting data for 1998 GNI and at least one outcome variable is listed in Table 7 The same information is presented for Gavi phases 2, 3, 4 and 5 in Tables 8, 9, 10 and 11 respectively. Data coverage improves over time. Note, however, that under-five mortality data is not available for 2011 and 2013, and expenditure data is not available for 2013, creating missing columns in tables 9, 10 and 11. 
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